Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study 

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Lorenza Rimassa presents a five-year overall survival analysis from the Phase 3 HIMALAYA study, demonstrating sustained survival benefits of the STRIDE regimen versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC).

Five-year Overall Survival (OS) and OS by Tumor Response Measures from the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)